Abstract 1997P
Background
B2 is a ligand for EphB4 (B4) that enhances tumor invasion, proliferation, survival and promotes angiogenesis. TCGA analysis of 409 bladder cancer patients (pts) showed B2 high (Hi) expression (34%) had poor OS vs. low (Lo) expression (66%) (Hazard Ratio- HR- 0.7 p=0.02). Our phase II trial of sEphB4-HSA- a B2 inhibitor- plus pembrolizumab in pre-treated mUC (N=70) showed an objective response rate (ORR) of 37%. Pts with B2 Hi had 52% ORR with 24% complete response (CR) (JCO PMID 35984996). In this study we investigated the association of B2 expression with OS and ORR in mUC.
Methods
Pts with mUC treated with a PD1/L1 antibody (Ab) were eligible if they had radiographic response data and tumor tissue for B2 testing. Demographics, disease characteristics, RECIST 1.1 radiographic response, and survival data were collected. Tumor specimens were analyzed for intensity of B2 expression using in-situ hybridization (ISH). Scores of 2-4 were marked Hi and 0-1 Lo. Descriptive statistics summarized the results. Log-rank and Fisher’s exact test were used for the associations of B2 status with OS and ORR using SAS 9.4.
Results
159 pts from University (U) of Southern California (USC, n=49), Dana Farber (DFCI, n=55), and U of California, Irvine (UCI, n=39) and U of Colorado (UC, n=16) were included. 116 pts were male (73%). Median age was 73. PD1/L1 Ab included pembrolizumab (n=121, 76%), atezolizumab (n=30, 19%) and nivolumab, avelumab, and durvalumab, 3%, 1%, and 1%, respectively. ORR defined as CR + partial response (PR) was 20% (95% CI 13%, 27%) (N=152 evaluable). ORR was 12% vs 33% in B2 Hi vs Lo, p=0.004. The median OS and its 95% CI was 16.5 (12.8, 21.0) months (N=159). Median OS was 13.5 (8.3, 16.7) mo. vs 20.6 (13.7, 39.8) mo. for B2 Hi vs Lo (HR 1.64 95% CI: 1.10, 2.44, p=0.014). Table: 1997P
Subgroup (%) | ||||||
B2 Any | All N=159 | USC n=49 | DFCI n=55 | UCI n=39 | UC n=16 | P |
Median age [range] | 73 [48-91] | 72 [48-87] | 73 [48-91] | 74 [48-90] | 69 [51-85] | |
Visceral metastases | 88 (55) | 26 (53) | 36 (65) | 17 (44) | 9 (56) | 0.21 |
ORR* | 31 (20) | 10 (20) | 11 (20) | 7 (22) | 3 (19) | 1.00 |
B2 Lo | 61 | 21 | 19 | 15 | 6 | 0.004 |
ORR | 20 (33) | 6 (29) | 7 (37) | 5 (33) | 2 (33) | |
B2 Hi | 91 (60) | 28 (57) | 36 (65) | 17 (53) | 10 (63) | |
ORR | 11 (12) | 4 (14) | 4 (11) | 2 (12) | 1 (10) | |
OS (mo.) median [95% CI] | 16.5 [12.8, 21.0] | 16.0 [8.1, 30.1] | 14.5 [9.0, 18.0] | 32.0 [13.3, 60.8] | 4.4 [3.1, 15.2] | 0.001 |
B2 Lo | 66 | 21 | 19 | 20 | 6 | 0.014 |
OS | 20.6 [13.7, 39.8] | 24.0 [9.2, NA] | 17.5 [7.3, 27.6] | 45.1 [10.8, 60.8] | 3.3 [1.67, 39.8] | |
B2 Hi | 93 (58) | 28 (57) | 36 (65) | 19 (49) | 10 (63) | |
OS | 13.5 [8.3, 16.7] | 8.8 [3.8, 30.1] | 13.8 [8.2, 16.7] | 21.0 [9.4, 32.8] | 4.4 [3.0, 9.4] |
Conclusions
B2 Hi was associated with poor OS and ORR to PD1/L1 Ab monotherapy in mUC. These data propose B2-B4 pathway as a mechanism of resistance to PD1/L1 Ab, a biomarker of outcome, and a therapeutic target.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
44P - Chemo-immunotherapy combination of mFOLFOX6, bevacizumab and atezolizumab after first-line therapy for advanced biliary tract cancer: The COMBATBIL imCORE trial
Presenter: Mariano Ponz-Sarvise
Session: Poster session 13
47P - First-line pembrolizumab (pembro) + gemcitabine and cisplatin (gem/cis) for advanced biliary tract cancer (BTC) in the China subpopulation from the phase III KEYNOTE-966 study
Presenter: Shukui Qin
Session: Poster session 13
48P - Pattern of expression, transcriptional states and clinical implications of tumour-infiltrating lymphocytes (TILs) in curatively-treated cholangiocarcinoma (CCA) patients (pts): The TILBIL study
Presenter: Maria Pia Quitadamo
Session: Poster session 13
49P - Prognostic relevance of baseline exosome-delivered PD-1, PD-L1, pan-BTN3As and BTN3A1 in advanced cholangiocarcinoma patients: Can immune checkpoints act as a sentinel for predicting survival?
Presenter: Lidia Rita Corsini
Session: Poster session 13
50P - Camrelizumab (Cam) combined with gemcitabine and cisplatin (GP) plus low-dose apatinib in first-line treatment of advanced biliary tract cancer (BTC)
Presenter: yunxin lu
Session: Poster session 13
52P - Cadonilimab in combined with gemcitabine and cisplatin in advanced biliary tract cancer (BicureX): A phase II, single-arm clinical trial
Presenter: Ji Ma
Session: Poster session 13